VIRIDIAN THERAPEUTICS INCVRDN
ASignal's systematic analysis rates VRDN as Neutral.
Reflects the latest available analysis · analyzed Oct 22, 2026
The case on VRDN
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (278.7% YoY)
- High cash reserves ($981.53M) relative to debt ($244.73M)
- Low debt-to-equity ratio (0.37x)
- Strong liquidity position (current ratio 16.95x)
- MACD histogram expanding above signal line indicating bullish momentum
- Overbought RSI at 72.73
- Price trading above upper Bollinger Band (22.92) suggesting overextension
- Negative operating margin (-44,460.56%)
- Negative return on equity (-65.74%) and return on assets (-30.16%)
- Negative free cash flow (-$275.50M)
- Extremely high price-to-sales ratio (36.63x) and EV/Revenue (27.67x)
See the full verdict on VRDN
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes VRDN
Most investors never get a second opinion, let alone several. ASignal runs VRDN past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.